PDCD1 and melanoma: In the past decade, the clinical management of patients with advanced melanoma was revolutionised by the use of anti-programmed cell death 1 (PD1) and/or anti-cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) immunotherapies, as well as BRAF/MEK inhibiting targeted therapies [3].